Couche-Tard advances deal talks for Japan's Seven & i with access to books
By Anton Bridge
(Reuters) -Alimentation Couche-Tard (ACT) and Japan's Seven & i said they have signed a non-disclosure agreement (NDA) that will give the Canadian company access to the Japanese retailer's financial data as it seeks a $47 billion acquisition.
The move represents progress in takeover talks for Couche-Tard, which operates the Circle-K convenience stores in Canada and the United States and has been trying to acquire Seven & i since August.
The detailed terms of the agreement will remain confidential, 7-Eleven operator Seven & i said in a statement on Thursday. The agreement also includes a "standstill" clause, which protects target companies from hostile takeovers.
Couche-Tard has said that access to "fulsome diligence information" may allow it to improve its proposal. The current offer of around $47 billion would already be the largest ever takeover of a Japanese company by a foreign buyer.
"The execution of the NDA is a positive step in the constructive engagement process with ACT," Paul Yonamine, who chairs Seven & i's independent special committee to examine bids, said in the company's statement.
Seven & i has previously said that until now Couche-Tard's refusal to agree to "standard protections" in a friendly deal, such as a standstill provision, has prevented an NDA from being signed.
It has also argued that antitrust hurdles in the U.S. are a principal barrier to the deal, but since March the two have been working together on finding a buyer for over 2,000 stores that are candidates for divestment.
While fielding the takeover bid, Seven & i has accelerated an overhaul of its management and business operations that includes selling off non-core business lines, appointing a new chief executive, and proposing four new board members.
Proxy adviser Institutional Shareholder Services (ISS) has recommended shareholders support the appointment of the new CEO, Stephen Dacus, and the new board members, according to a report seen by Reuters.
Seven & i shares rose 2.7% in early trade in Tokyo on Thursday, outperforming the Nikkei index.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
6 Ways To Sidestep Rising Car Prices If Tariffs Take Hold
With auto prices already inflated since the pandemic, proposed tariffs on imported vehicles could make matters worse. According to Reuters, tariffs could add as much as $12,000 to the cost of an imported car, a blow most Americans simply can't absorb. A recent JDMBUYSELL survey found that nearly 2 in 5 say they can't afford any increase in vehicle costs, and over half believe the proposed trade measures are more political than practical. Learn More: Read Next: While 47% still hope to buy a car in the next year, most are rethinking how. Here's how many are navigating the financial landmines and avoiding sticker shock if tariffs take hold. Used cars are quickly becoming the go-to workaround. With 17% already shifting focus to the secondhand market, the demand for reliable, lower-mileage models is expected to spike. Among Gen Z, used cars are the clear frontrunner, with 37% saying they'll buy pre-owned instead of paying tariff-inflated prices for new imports. Check Out: Thirty-seven percent of U.S. drivers said they'd opt for an American-made car if tariffs hike prices. It's a practical pivot that could save thousands. Domestic automakers stand to gain the most, especially from boomers and Gen Xers, who are drawing a hard line on price. For many, the trade-off in style or features is worth avoiding the financial hit. Twenty-five percent plan to downsize or downgrade their expectations. Swapping out a premium brand for a budget-friendly make or choosing a lower trim level are becoming popular strategies. Among Gen Z and millennials, flexibility matters more than prestige — and that mindset is spreading across other age groups as prices climb. Making savings over the longer term, with things like greater fuel efficiency, is also shaping decisions around buying. Twenty-two percent say they'd shift to more efficient vehicles to offset higher upfront costs, and the logic makes sense; if prices go up, saving money on things like fuel matters even more. More than half of Americans plan to hit pause on buying a car altogether. Delayed deals are now a key coping mechanism, especially for low- to middle-income earners. For buyers who aren't under pressure to upgrade, waiting out the policy changes could avoid thousands in extra costs. Despite the hype, only 6% said they'd switch to an electric vehicle (EV) like Tesla or Rivian to dodge tariff costs. But younger buyers seem more open to it, with nearly 1 in 3 Gen Zers at least considering the switch, and 14% said they'd go electric even if prices rise, a rate nearly five times higher than among boomers. The path forward isn't clear. With 40% of Americans expressing zero faith in federal trade policy to protect ordinary drivers, most aren't waiting for government solutions. Instead, they're adjusting buying plans, exploring alternatives and bracing for more expensive decisions ahead. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 Here's the Minimum Salary Required To Be Considered Upper Class in 2025 Mark Cuban Tells Americans To Stock Up on Consumables as Trump's Tariffs Hit -- Here's What To Buy This article originally appeared on 6 Ways To Sidestep Rising Car Prices If Tariffs Take Hold
Yahoo
32 minutes ago
- Yahoo
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ('Aquestive' or the 'Company'), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for Anaphylm™ in the treatment of Type 1 allergic reactions, including anaphylaxis, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026. The FDA reiterated that it may decide to conduct an Advisory Committee meeting for the approval of Anaphylm. If approved by the FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States. 'Anaphylm represents a breakthrough in anaphylaxis treatment, if approved by FDA, being the first and only device-free, orally delivered epinephrine medicine,' said Dan Barber, President and Chief Executive Officer of Aquestive. 'We designed Anaphylm to fit seamlessly into the patient's daily life. It's thinner than a credit card and requires no special storage, so patients can keep it in their phone case, wallet, or pocket – Anaphylm can go everywhere you go, without the bulk of even the smallest FDA-approved device for this patient population.' 'Our clinical data demonstrates Anaphylm's ability to rapidly deliver epinephrine absorption orally,' Mr. Barber continued. 'With the FDA's acceptance of our NDA, we're one step closer to getting this life-saving innovation in the hands of the patients and caregivers who need it most.' "Anaphylaxis is an unpredictable, severe allergic reaction that can be life-threatening within minutes. While epinephrine remains the only FDA-approved first-line treatment, too many at-risk individuals don't carry it consistently or hesitate to use it when seconds count," said Dr. David Stukus, M.D., Professor of Clinical Pediatrics and Director of the Food Allergy Treatment Center at Nationwide Children's Hospital and The Ohio State University College of Medicine. "The reality is stark: epinephrine can only save lives if people have it available and feel confident using it immediately. This potential drug product addresses the two biggest barriers we hear from patients – fear of administration and the inconvenience of carrying bulky devices. An oral, no-needle approach could be transformative for anaphylaxis care." About Anaphylm™ (epinephrine) Sublingual Film Anaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. Anaphylm has the potential to be the first and only sublingual epinephrine film, providing a novel, patient-friendly alternative that seeks to eliminate the challenges patients face with needle-based available epinephrine products. The Anaphylm trade name for AQST-109 has been conditionally approved by the U.S. Food and Drug Administration (FDA). Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate. About Aquestive Therapeutics Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions. For more information, visit and follow us on LinkedIn. Forward-Looking Statement Certain statements in this press release include 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'estimate,' 'intend,' 'may,' 'will,' or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film through clinical development and approval by the FDA, and the following launch of Anaphylm, if approved by the FDA; Anaphylm's potential as a non-device, orally delivered epinephrine treatment option for severe allergic reactions, including anaphylaxis, and that it could overcome some of the current barriers to treatment, if approved by the FDA; that the FDA may hold an Advisory Committee meeting for the approval of Anaphylm; the advancement of the Company's product candidate AQST-108 through clinical development and approval by the FDA for possible various dermatology conditions; the potential benefits our products and product candidates could bring to patients; and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm and AQST-108; risk of delays in advancement of the regulatory approval process through the FDA of our product candidates, including with respect to the approval of our filed NDA for Anaphylm, or the failure to receive FDA approval at all for any of our product candidates, including Anaphylm and AQST-108; risk of the Company's ability to generate sufficient clinical data for approval of our product candidates, including with respect to our pharmacokinetic and pharmacodynamic comparability submission for FDA approval of Anaphylm; risk of the Company's ability to address the FDA's comments on the Company's clinical trials and other concerns identified in the FDA's Type C meeting minutes and filing review letter for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risk that the FDA may require that an Advisory Committee be required for the approval of Anaphylm and that the Company is able to address any concerns raised by such Advisory Committee or the FDA after review of the advice from the Advisory Committee; risk of the success of any competing products, including generics; risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of sufficient capital and cash resources, including sufficient access to available debt and equity financing, including under our ATM facility, and revenues from operations, to satisfy all of our short-term and longer-term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund commercialization activities relating to fund future clinical development and commercial activities for our product candidates, including Anaphylm, should these product candidates be approved by the FDA; risk of eroding market share for Suboxone® and risk as a sunsetting product, which accounts for the substantial part of our current operating revenue; risk of default of our debt instruments; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance in the U.S. of Anaphylm and our other product candidates, should these product candidates be approved by the FDA, and for our licensed products in the U.S. and abroad; risk of the size and growth of our product markets; risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to our products; risk that our patent applications for our product candidates, including for Anaphylm, will not be timely issued, or issued at all, by the U.S. Patent and Trademark Office (USPTO); risk of unexpected patent developments; risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and products candidates and product pricing, reimbursement or access therefor; risk of loss of significant customers; risks related to claims and legal proceedings against Aquestive including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; risk of product recalls and withdrawals; risks related to any disruptions in our information technology networks and systems, including the impact of cybersecurity attacks; risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; risk of adverse developments affecting the financial services industry; risks related to inflation and rising interest rates; risks related to the impact of the COVID-19 global pandemic and other pandemic diseases on our business; risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions; risks related to uncertainties about U.S. government initiatives and their impact on our business, including imposition of tariffs and other trade restrictions; and other unusual items; and other uncertainties affecting us including those described in the "Risk Factors" section and in other sections included in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law. PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners. Investor Contact:Brian Korbastr in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
WILMINGTON, Del., June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced a strategic investor relations partnership with astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector. "We are pleased to partner with astr partners at this important inflection point for NRx, as we have filed an ANDA, are on the precipice of completing two NDA filings and are actively acquiring profitable interventional psychiatry clinics," said Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. "Their depth of experience in biotech investor relations, broad relationships with specialist investors and the right investment banks, as well as their commitment to precision messaging, make astr the ideal team to help amplify the ongoing value story NRx and HOPE." astr partners was founded by the industry veterans from The Trout Group, including Jonathan Fassberg and Brian Korb, who bring decades of combined experience in investor relations and healthcare capital markets. The Trout Group was the global leader in biotech investor relations, which was sold to PNC Bank. Jonathan and Brian later held senior roles at Solebury Trout and Oppenheimer & Co. The astr team works closely with biotech companies across a range of development stages — from early clinical to commercial — with a strong focus on strategic positioning and institutional engagement. "We're thrilled to support NRx and HOPE as they advance meaningful neuropsychiatry therapies toward patients with critical unmet needs," said Jonathan Fassberg and Brian Korb, Managing Partners of astr. "Our team is excited to collaborate closely with NRx and HOPE to elevate their visibility and strengthen their relationships across the investment community at this key inflection point." astr partners will work with the NRx and HOPE executive teams to execute a comprehensive investor relations program that includes investor targeting, message development, earnings preparation, conference support, and proactive investor engagement. About NRx Pharmaceuticals, Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy, for suicidal treatment-resistant bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as a treatment for complicated UTI. NRx recently filed an Abbreviated New Drug Application (ANDA) for NRX-100 (preservative free IV ketamine) for use in ketamine's currently approved indications. Additionally, the Company has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office. About HOPE Therapeutics, Therapeutics, Inc. ( a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, whether the USPTO approves the Company's patent, and whether the FDA will approve the Company's NDA. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Brian Korb Co-CEO, Hope Therapeutics, Inc. Managing Partner, astr partners Chief Business Officer, NRx Pharmaceuticals, Inc. (917) 653-5122 mduffy@ View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
